Conversely, HDAC inhibitors have been shown to exert cytotoxicity preferentially in TP53-mutant cancer cell lines [10,11], though this observation is controversial as there have been contradicting reports suggesting different HDAC inhibitors may have different effects on TP53 mutant or wild-type cells [12]. The gene discussed is TP53; the disease is cancer.